Navigation Links
Trevena Granted Key Composition of Matter Patent for TRV027 in U.S.
Date:7/17/2013

KING OF PRUSSIA, Pa., July 17, 2013 /PRNewswire/ -- Trevena, Inc., (Trevena) a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today that the United States Patent and Trademark Office has granted Trevena a composition of matter patent covering its development product TRV027.  United States Patent No. 8,486,885 entitled "Beta-Arrestin Effectors and Composition and Methods of Use Thereof," is expected to provide coverage for TRV027 until at least July 2031.    

TRV027 is an experimental intravenous drug for the treatment of acute decompensated heart failure (ADHF), currently in mid-stage clinical trials.  It is a novel beta-arrestin biased ligand of the angiotensin II type 1 receptor that combines the proven benefits of angiotensin blockade with new beta-arrestin-mediated biology to preserve cardiac and renal function.  Trevena recently entered into a collaborative licensing option agreement for the development of TRV027 with Forest Laboratories Inc. (NYSE: FRX).  The company expects to commence a 500-patient multi-center Phase 2b clinical trial for TRV027 in ADHF patients by year end.

"This core patent provides the foundation for broad and enforceable intellectual property protection for TRV027, and is followed by a series of patent applications made by Trevena to protect our growing pipeline of GPCR biased ligands in key markets around the world,"  said Maxine Gowen, Trevena's President and Chief Executive Officer.  David Solomon, Forest's SVP of Corporate Development & Strategic Planning, and a Board member at Trevena, added, "This issued patent enhances the value potential of TRV027, and provides an essential platform from which to drive its commercialization."  

Trevena recently presented the results of
'/>"/>

SOURCE Trevena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure
2. Trevena, Inc. to Present at the 12th Annual Needham Healthcare Conference
3. CorMedix Granted Extension of NYSE MKT Listing
4. QRxPharma Granted US Patent On Hybrid Opioids
5. Mapi Pharma Granted United States Patent Covering Glatiramer Depot for Multiple Sclerosis
6. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
7. Bayers Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
8. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
9. Cedarburg Hauser Granted DEA Registration for Denver Manufacturing Facility
10. KAHR Medical Granted U.S. Patent Approval for One of its Lead Products in Development, KAHR-101
11. US Patent Granted to RBC Life Sciences for Supplement that Supports Cognitive Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... YORK, Feb. 17, 2011 Reportlinker.com ... report is available in its catalogue: ... 2016 - Cephalosporins, Penicillins, Macrolides and ... http://www.reportlinker.com/p0397051/Anti-Bacterials-Market-to-2016---Cephalosporins-Penicillins-Macrolides-and-Fluoroquinolones-to-Drive-the-Anti-Bacterials-Market.html ...
... Reportlinker.com announces that a new market research ... Early Stage Drug Discovery in Disease Segments ... Gene Therapies http://www.reportlinker.com/p0397053/Early-Stage-Drug-Discovery-in-Disease-Segments---Innovation-Focuses-on-Stem-Cell-Therapies-and-Gene-Therapies.html ... Segments - Innovation Focuses on Stem Cell Therapies ...
Cached Medicine Technology:Reportlinker Adds Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market 2Reportlinker Adds Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market 3Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies 2Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies 3Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies 4
(Date:7/9/2014)... an innovative tool that captures heretofore hidden ways that ... a protein that makes breast cancer cells more likely ... trigger cancer,s spread in part by blocking two other ... that suggests these two disease processes could have unexpected ... July 10 issue of Nature , points to ...
(Date:7/9/2014)... New findings from Fox Chase Cancer Center paint a ... subset of breast cancers that have spread to the ... Tumors that grow into the skin, regardless of size ... classified as stage III and called "locally advanced" ... of cancer, often with poor survival. Locally advanced breast ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
(Date:7/9/2014)... has been a sharp increase in the number of ... the online, interactive service that allows patients to view ... schedule appointments, and renew prescriptions. , Over a six-year ... each year increased five-fold, while the number of ... to a study by Dr. David Gerber , ...
(Date:7/9/2014)... watching World Cup highlights, Brian Williams refreshing old school ... positions on railings. A University of Colorado Cancer Center ... shows that YouTube also allows researchers, journals, and health ... of skin cancer and prevention. , "No matter what ... how we communicate around the world," says Chante Karimkhani, ...
Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study of dermatology on YouTube shows new ways science reaches public 2
... China is no cause for alarm , , MONDAY, April ... case of human-to-human transmission of bird flu in China. ... there,s a genetic component to human-to-human transmission of this ... suggests that there,s some genetic component to resistance in ...
... powder-free, ANAHEIM, Calif., April 7, 2008 ... year,s Association of PeriOperative,Registered Nurses (AORN) 55th Congress ... reported being "very concerned" about the surgical,complications related ... facility was powder-free. Powdered gloves have been implicated ...
... The Chehalis,Confederated Tribes will host a special ... Casino May 17 and 18, tribal officials,announced this ... Honor Veterans Benefit," will provide much needed support ... the Freedoms Foundation,s,Return to Honor Program., "We,re ...
... Media, Inc. (AMI),today said that it has made ... to be disclosed on a monthly basis to ... Agreement., The information, which includes the average ... the period April 2007,through March 2008, as well ...
... Pa., April 7, 2008 Genaera,Corporation (Nasdaq: ... Rule 4350(b)(1)(B), that the audit report included in ... fiscal year ended December 31,2007 contained an unqualified ... KPMG LLP, which included a "going concern",explanatory paragraph. ...
... Pa., April 7, 2008 Consumers who,purchased raw ... Bethlehem, Clarion,County, and Clark and Elaine Duncan,s farm ... discard it immediately due to the risk of,Listeria ... Raw milk is milk that has not been ...
Cached Medicine News:Health News:Probable Case of Human-to-Human Bird Flu Transmission Reported 2Health News:Probable Case of Human-to-Human Bird Flu Transmission Reported 3Health News:Operating Room Nurses are Concerned about Complications Associated with Powdered Gloves 2Health News:Operating Room Nurses are Concerned about Complications Associated with Powdered Gloves 3Health News:Operating Room Nurses are Concerned about Complications Associated with Powdered Gloves 4Health News:Chehalis Tribes Announce Benefit to Help Returning Combat Veterans 2Health News:Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph 2Health News:Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph 3
EIA Kit for the detection of progesterone....
No cross-reaction with human pro-insulin and C-peptide....
... innovative GenePaint technology, the investigation of gene ... easier. The GenePaint system automates efficiently and ... required for performing ISH on cells or ... fixing, staining, washing and hybridization procedures. With ...
... (17alpha-OH-P) is a steroid produced in the ... defined physiological role except as a precursor ... be converted to cortisol by the sequential ... the adrenal glands and ovaries, 17alpha-OH-P can ...
Medicine Products: